Wednesday December 19, 2018

Researchers Identified Protein Associated With Breast Cancer

In HER2-positive breast cancers, cells with high levels of AXL are more likely to detach from tumours to form metastases.

0
//
High vitamin D harming Breast Cancer, Pixabay
Republish
Reprint

Researchers have found that a protein that, once deactivated, could prevent the spread of an aggressive type of breast cancer to other sites in the body, a process known as metastasis.

In their study, published in the journal Cell Reports, the researchers demonstrated that a protein, AXL, influences the occurrence of metastasis in HER2-positive cancer, an aggressive type that accounts for 20 per cent of breast cancers.

In HER2-positive breast cancers, cells with high levels of AXL are more likely to detach from tumours to form metastases.

Researchers have found that a protein that, once deactivated, could prevent the spread of an aggressive type of breast cancer to other sites in the body, a process known as metastasis.
Representational Image, pixabay

The research was done on mice and with samples of tumour cells taken from cancer patients in Montreal, Canada.

In women with HER2-positive cancer, it was found that the less AXL is present, the better the survival rate.

Also Read: To Fight Air Pollution, Delhi Scientists Are Turning Smoke Into Ink

Previously, researchers had linked the AXL protein to another type of cancer, triple negative breast cancer, but its role in in HER2-positive cancer was not known.

“Based on this discovery, a treatment targeting AXL could reduce the risk of metastasis,” said one of the researchers Jean-Francois Cote, Professor at Universite de Montreal in Canada. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

New Drug to Give Hopes to Bone Marrow Cancer Patients

It reduced the risk of progression or death by more than 50 per cent in both groups

0
Cancer
Cancer Ribbon. Pixabay

A therapeutic drug has been found to improve outcomes and survival rates for patients with a serious type of bone marrow cancer.

In a clinical trial by researchers at Newcastle University in Britain, patients with newly diagnosed myeloma were treated with a drug called lenalidomide.

The results, published in the journal The Lancet Oncology, showed an improvement for those who received lenalidomide drug, compared to those not receiving it.

“This is a major breakthrough as it shows that the long-term use of lenalidomide significantly improves the time myeloma patients stay in remission after initial therapy,” said Professor Graham Jackson from the Northern Institute for Cancer Research at Newcastle.

Myeloma is a cancer of the plasma cells and it can affect several areas of the body, such as the spine, skull, pelvis and ribs. Current treatment usually involves chemotherapy and a stem-cell transplant.

cancer
New drug offers hope for bone marrow cancer patients. Pixabay

“It is a huge step and, importantly, identifies that for younger patients lenalidomide improves their overall survival for this difficult-to-treat bone marrow cancer,” Jackson said.

“Our research highlights that lenalidomide should be considered for newly diagnosed patients following stem-cell transplantation,” he added.

As part of the study, a total of 1,137 newly diagnosed patients were randomly assigned to lenalidomide maintenance therapy and 834 patients to observation – this was after they completed their initial treatment.

Also Read- Narendra Modi Accuses Congress of Aiding Those Who Want to Weaken Army

The results show that lenalidomide can prolong the average remission time by more than two years in younger patients and by well over a year in older, less fit patients.

It reduced the risk of progression or death by more than 50 per cent in both groups. (IANS)